The risk that healthcare system reforms involving healthcare cost containment, advances in medical care and the adoption of new tests will affect demand for and sales of testing and diagnostic products, as well as business performance. This includes lower sales in the hematology and blood coagulation fields resulting from China’s healthcare cost containment policies.